Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellyan Biotechnology CoHKPD -4.33%21 Interest Coverage is 3.35 as of Sep. 2025, which is 83% below its 10-year median of 20.16. GuruFocus rates HKPD with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 89 Medical Distribution companies, Cellyan Biotechnology Co ranks worse than 1123594.38% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Cellyan Biotechnology Co's
Operating Income
for the
six
months ended in Sep. 2025 was $0.21 Mil. Cellyan Biotechnology Co's Interest Expense for the
six
months ended in Sep. 2025 was $-0.06 Mil.
Cellyan Biotechnology Co's interest coverage for the quarter that ended in Sep. 2025 was 3.35.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Cellyan Biotechnology Co's Interest Coverage or its related term are showing as below:
HKPD's Interest Coverage is not ranked *
in the Medical Distribution industry.
Industry Median: 6.23 * Ranked among companies with meaningful Interest Coverage only.
Cellyan Biotechnology Co (NAS:HKPD) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Cellyan Biotechnology Co Interest Coverage Related Terms
Cellyan Biotechnology Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
HKPD vs COSM, SNYR, YI: Interest Coverage Comparison
For the Medical Distribution subindustry, Cellyan Biotechnology Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellyan Biotechnology Co Interest Coverage vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Cellyan Biotechnology Co's Interest Coverage falls into.
Cellyan Biotechnology Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellyan Biotechnology Co (HKPD) has a Interest Coverage of 3.35 as of Sep. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Cellyan Biotechnology Co and its competitors. This is 83% below median its historical median of 20.16. According to the industry distribution chart, Cellyan Biotechnology Co ranks #999999 out of 89 companies in the Medical Distribution industry.
Is Cellyan Biotechnology Co's Interest Coverage too high?
Cellyan Biotechnology Co's current Interest Coverage of 3.35 is 83% below median its 10-year median of 20.16. The Medical Distribution industry median Interest Coverage is 6.23. Cellyan Biotechnology Co's value of 3.35 is 46.2% below this industry median. Based on the distribution chart, Cellyan Biotechnology Co ranks #999999 out of 89 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cellyan Biotechnology Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Interest Coverage compare to COSM and SNYR?
According to the Medical Distribution industry distribution chart, Cellyan Biotechnology Co ranks #999999 out of 89 companies for Interest Coverage. This places Cellyan Biotechnology Co in the lower half of its industry. The industry median Interest Coverage is 6.23. Cellyan Biotechnology Co's value of 3.35 is 46.2% below this benchmark. While the company's 10-year median is 20.16 vs. the industry median of 6.23, Cellyan Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Distribution company?
The median Interest Coverage among Medical Distribution companies is 6.23, based on 89 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cellyan Biotechnology Co's current Interest Coverage of 3.35 is 46.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Cellyan Biotechnology Co and its competitors. For the Medical Distribution industry, the median Interest Coverage is 6.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellyan Biotechnology Co's current Interest Coverage is 3.35, which is 83% below median its own 10-year median of 20.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Interest Coverage of 3.35. The current Interest Coverage is 3.35, which is 83% below median its 10-year median of 20.16 and 46.2% below the Medical Distribution industry median of 6.23. Cellyan Biotechnology Co's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Interest Coverage is 3.35 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
21GF Score
Get the complete analysis for HKPD
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKPD has been successfully added to your 
